demonstrated that an IV bolus of andexanet alfa immediately and significantly reduced the anticoagulation activity of Bristol - Myers Squibb ( BMY -1.4% ) and Pfizer's ( PFE -1.3% ) direct Factor Xa inhibitor Eliquis (apixaban). The results were
Bristol - Myers Squibb ( BMY -1% ) will report Q3 results on October 24. The conference call will begin at 10:30 am ET. Consensus view is EPS of $0.42 on revenues of $3.8B. Post your comment!
category with $135M. Most of this (90%) went to a Southern California hospital network for royalties. Bristol - Myers Squibb (NYSE: BMY ) was #1 in the research category with $329M which, according to the company, was largely the value
The European Medicines Agency (EMA) validates Bristol - Myers Squibb 's ( BMY -0.5% ) Marketing Authorization Application (MAA) for Opdivo ( nivolumab ) for review for the treatment of patients with
Mekinist/Tafinlar, which is already on the market, and the increasing use of immuno-oncology drugs such as Bristol - Myers Squibb ’s Yervoy and Opdivo and Merck’s Keytruda, we think that the competitive landscape will be challenging
At the ESMO Congress in Madrid, Spain, Bristol - Myers Squibb (NYSE: BMY ) presented results from an interim analysis of a Phase 3 clinical trial of its Fast Track-designated PD-1 immune checkpoint
MADRID, Sept 29 (Reuters) - Bristol - Myers Squibb 's immunotherapy drug Opdivo produced markedly improved response rates with fewer toxic side effects compared to chemotherapy in a major melanoma study, underscoring its potential as a new treatment option.
Sept 26 (Reuters) - The U.S. Food and Drug Administration has granted a six-month, priority review to Bristol - Myers Squibb Co 's application for immuno-oncology drug Opdivo as a treatment for previously treated melanoma, the company said on Friday.
PFE ), Johnson & Johnson (NYSE: JNJ ), GlaxoSmithKline (NYSE: GSK ), Novartis (NYSE: NVS ), & Bristol - Myers Squibb (NYSE: BMY ) (Figure 1.). Merck is up 20% YTD, but it also offers the stability of a blue chip and a 3.1
that stands out as greatly overvalued is Bristol - Myers Squibb (NYSE: BMY ). Bristol - Myers Squibb is far too overpriced, when compared to ..... valuation metrics, especially when compared to Bristol - Myers Squibb , and J&J will provide enough